RIGI and cancer: Here, we demonstrate the feasibility of a novel combinatorial therapeutic approach against HPV-associated cancers based on cancer cell-intrinsic cell death triggered by drug-targeted activation of the RIG-I pathway, which in turn potentiates existing anticancer therapies.